Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARCHNASDAQ:CERENYSE:CNXNYSE:HCC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCHArch Biopartners$134.83$134.83$116.44▼$177.88N/AN/A381,032 shsN/ACERECerevel Therapeutics$44.96$43.67$19.59▼$44.99$8.19B1.41.71 million shsN/ACNXCNX Resources$32.02-1.2%$32.11$23.85▼$41.93$4.63B0.662.61 million shs2.61 million shsHCCWarrior Met Coal$50.01-0.7%$46.59$38.00▼$75.15$2.63B0.67838,036 shs892,406 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCHArch Biopartners0.00%0.00%0.00%0.00%+13,482,999,900.00%CERECerevel Therapeutics0.00%0.00%0.00%0.00%+11.56%CNXCNX Resources0.00%-5.33%+2.91%+9.31%+29.06%HCCWarrior Met Coal0.00%+14.13%+7.21%+23.47%-31.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCHArch BiopartnersN/AN/AN/AN/AN/AN/AN/AN/ACERECerevel TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACNXCNX Resources3.351 of 5 stars1.81.00.00.01.93.33.1HCCWarrior Met Coal4.2864 of 5 stars3.31.01.70.02.81.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCHArch Biopartners 0.00N/AN/AN/ACERECerevel Therapeutics 0.00N/AN/AN/ACNXCNX Resources 1.60Reduce$31.58-1.36% DownsideHCCWarrior Met Coal 2.50Moderate Buy$63.6727.31% UpsideCurrent Analyst Ratings BreakdownLatest CERE, CNX, HCC, and ARCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CNXCNX ResourcesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$21.00 ➝ $25.005/13/2025CNXCNX ResourcesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$35.00 ➝ $36.005/7/2025HCCWarrior Met CoalUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$68.00 ➝ $50.004/25/2025CNXCNX ResourcesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/22/2025CNXCNX ResourcesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $21.004/15/2025CNXCNX ResourcesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight$31.004/11/2025CNXCNX ResourcesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Underperform ➝ Sector Perform$33.004/11/2025HCCWarrior Met CoalB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $76.004/7/2025CNXCNX ResourcesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$34.00 ➝ $35.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCHArch BiopartnersN/AN/AN/AN/AN/AN/ACERECerevel TherapeuticsN/AN/AN/AN/A$3.71 per shareN/ACNXCNX Resources$1.27B3.66$5.23 per share6.12$27.45 per share1.17HCCWarrior Met Coal$1.32B1.99$8.00 per share6.25$39.97 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCHArch BiopartnersN/AN/A0.00∞N/AN/AN/AN/AN/ACERECerevel Therapeutics-$432.84M-$2.73N/AN/AN/AN/A-98.94%-45.07%N/ACNXCNX Resources-$90.49M-$2.06N/A11.900.30-30.59%7.86%3.71%7/24/2025 (Estimated)HCCWarrior Met Coal$250.60M$2.0124.885.58N/A7.98%5.41%4.34%7/30/2025 (Estimated)Latest CERE, CNX, HCC, and ARCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025CNXCNX Resources$0.40N/AN/AN/A$467.33 millionN/A4/30/2025Q1 2025HCCWarrior Met Coal-$0.05-$0.16-$0.11-$0.16$296.39 million$299.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCHArch BiopartnersN/AN/AN/AN/AN/ACERECerevel TherapeuticsN/AN/AN/AN/AN/ACNXCNX ResourcesN/AN/AN/AN/AN/AHCCWarrior Met Coal$0.320.64%N/A15.92%1 YearsLatest CERE, CNX, HCC, and ARCH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/23/2025HCCWarrior Met Coalquarterly$0.080.65%5/5/20255/5/20255/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCHArch BiopartnersN/AN/AN/ACERECerevel Therapeutics0.6010.2210.22CNXCNX Resources0.630.270.25HCCWarrior Met Coal0.095.144.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCHArch BiopartnersN/ACERECerevel Therapeutics87.73%CNXCNX Resources95.16%HCCWarrior Met Coal92.28%Insider OwnershipCompanyInsider OwnershipARCHArch BiopartnersN/ACERECerevel Therapeutics5.10%CNXCNX Resources3.10%HCCWarrior Met Coal2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCHArch BiopartnersN/AN/AN/AN/ACERECerevel Therapeutics300182.20 million172.90 millionOptionableCNXCNX Resources470144.72 million140.24 millionOptionableHCCWarrior Met Coal1,33652.56 million51.46 millionOptionableCERE, CNX, HCC, and ARCH HeadlinesRecent News About These CompaniesHCC Warrior Met Coal, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comWarrior Met Coal (NYSE:HCC) Shares Gap Up - Here's WhyJuly 2, 2025 | marketbeat.com27,500 Shares in Warrior Met Coal (NYSE:HCC) Acquired by Skylands Capital LLCJune 29, 2025 | marketbeat.comCWA Asset Management Group LLC Buys New Holdings in Warrior Met Coal (NYSE:HCC)June 22, 2025 | marketbeat.comWarrior Met Coal (NYSE:HCC) Stock Price Down 4.8% - Here's What HappenedJune 20, 2025 | marketbeat.comKingdom Capital Advisors Decided to Sell its Investments in Warrior Met Coal (HCC)June 19, 2025 | finance.yahoo.comKingdom Capital Advisors Decided to Sell its Investments in Warrior Met Coal (HCC)June 19, 2025 | insidermonkey.comExchange Traded Concepts LLC Decreases Stock Holdings in Warrior Met Coal (NYSE:HCC)June 19, 2025 | marketbeat.comWarrior Met Coal, Inc. (NYSE:HCC) Holdings Raised by GAMMA Investing LLCJune 13, 2025 | marketbeat.comRhumbline Advisers Decreases Stock Position in Warrior Met Coal, Inc. (NYSE:HCC)June 12, 2025 | marketbeat.comMercuria Capital Strategies LLC Decreases Stock Holdings in Warrior Met Coal, Inc. (NYSE:HCC)June 8, 2025 | marketbeat.comVest Financial LLC Takes $2.59 Million Position in Warrior Met Coal, Inc. (NYSE:HCC)June 8, 2025 | marketbeat.comHere's What's Concerning About Warrior Met Coal's (NYSE:HCC) Returns On CapitalJune 2, 2025 | finance.yahoo.comInsider Buying: Jack Richardson Acquires Shares of Warrior Met Coal Inc (HCC)May 23, 2025 | gurufocus.comSomerset International Installs Six Tailings Dewatering Units at Warrior Met Coal's Blue Creek Mine, the Largest U.S. Coal Facility Without a Tailings DamMay 22, 2025 | businesswire.comWarrior Met Coal Stock Price, Quotes and Forecasts | NYSE:HCC | BenzingaMay 18, 2025 | benzinga.comWarrior Met Coal, Inc. (HCC): A Bull Case TheoryMay 13, 2025 | finance.yahoo.comEarnings call transcript: Warrior Met Coal Q1 2025 misses EPS forecastsMay 2, 2025 | investing.comWarrior Met Coal Posts Q1 LossMay 2, 2025 | nasdaq.comWarrior Met Coal projects Blue Creek ramp-up and anticipates $995M-$1.1B total project costMay 1, 2025 | msn.comWarrior Met Coal Inc (HCC) Q1 2025 Earnings Call Highlights: Navigating Market Challenges with ...May 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeGovernment Mandate Sends eVTOL Stocks FlyingBy Jeffrey Neal Johnson | June 10, 2025View Government Mandate Sends eVTOL Stocks FlyingCERE, CNX, HCC, and ARCH Company DescriptionsArch Biopartners NYSE:ARCH$134.83 0.00 (0.00%) As of 01/14/2025Cerevel Therapeutics NASDAQ:CERECerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.CNX Resources NYSE:CNX$32.02 -0.39 (-1.20%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$31.99 -0.03 (-0.09%) As of 07/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNX Resources Corporation, an independent natural gas and midstream company, engages in the acquisition, exploration, development, and production of natural gas properties in the Appalachian Basin. The company operates in two segments, Shale and Coalbed Methane (CBM). It produces and sells pipeline quality natural gas primarily for gas wholesalers. The company owns rights to extract natural gas from shale properties in Pennsylvania, West Virginia, and Ohio, as well as rights to extract natural gas from other shale and shallow oil and gas formations in Illinois, Indiana, New York, and Virginia. It also owns rights to extract CBM in Virginia, West Virginia, Pennsylvania, Ohio, Illinois, Indiana, and New Mexico. In addition, the company designs, builds, and operates natural gas gathering systems to move gas from the wellhead to interstate pipelines or other local sales points; owns and operates approximately 2,600 miles of natural gas gathering pipelines, as well as various natural gas processing facilities. It also offers turn-key solutions for water sourcing, delivery, and disposal for its natural gas operations and for third parties. The company was formerly known as CONSOL Energy Inc. and changed its name to CNX Resources Corporation in November 2017. CNX Resources Corporation was founded in 1860 and is headquartered in Canonsburg, Pennsylvania.Warrior Met Coal NYSE:HCC$50.01 -0.33 (-0.66%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$49.86 -0.16 (-0.31%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.